maobin5

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

AChE/BChE/MAO-B-IN-5 is a multi-target inhibitor capable of crossing the blood-brain barrier, targeting cholinesterases (AChE and BChE) and monoamine oxidase MAO-B. It exhibits IC50 values of 0.24 µM for AChE, 6.29 µM for BChE, and 0.11 µM for MAO-B. AChE/BChE/MAO-B-IN-5 holds potential for research in neurodegenerative diseases such as Alzheimer's disease.

AChE/MAO-B-IN-5 is a dual inhibitor of AChE and MAO-B. It is utilized in the investigation of Alzheimer's disease.

MAO-B-IN-51 (Compound 8f) is an orally active and selective MAO-B inhibitor that can cross the blood-brain barrier, with an IC50 value of 48.9 nM (MDS). It is known to enhance long-term memory.

MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC50 value of 0.06 μM. It effectively inhibits the aggregation of Aβ40/42 and Tau proteins, with an overall IC50 of approximately 1 μM. Additionally, MAO-B-IN-50 exhibits potent and selective AChE inhibitory activity (IC50 = 1.78 μM). This compound is useful in Alzheimer's disease research.

hMAO-B-IN-5 is a potent reversible and selective human monoamine oxidase hMAO-B inhibitor (IC50:0.12μM). hMAO-B-IN-5 can cross the blood-brain barrier and can be used in the study of Parkinson's disease. It is a promising compound in the treatment and diagnosis of central nervous system diseases.